Laventair Ellipta (previously Laventair) (umeclidinium bromide;vilanterol)
- Region
- 🇪🇺 EU
- Active substance
- umeclidinium bromide;vilanterol
- Company
- GlaxoSmithKline Trading Services Limited
- Status
- Authorised
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- CHMP opinion
- Thu 20 Feb 2014
- EU approval
- Thu 08 May 2014
- Application
- EMEA/H/C/003754
- ATC
- R03AL03
- Official record
- www.ema.europa.eu
Indication
Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Anoro Ellipta (previously Anoro) Authorised · GlaxoSmithKline Trading Services Limited
Follow Laventair Ellipta (previously Laventair)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.